Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Prevention of AF and AKI in CABG (STENOTYPE)
NCT05852704Phase 3Recruiting
- Sponsor
- Region Örebro län
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dapagliflozin in Atrial fibrillation (AFib), acute kidney injury (AKI), sponsored by Region Örebro län. Started Apr 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05852704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852704.